{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:04:29Z","timestamp":1791572669388,"version":"4.3.4"},"reference-count":134,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T00:00:00Z","timestamp":1298505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["opencardiovascularmedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOCMJ"],"published-print":{"date-parts":[[2011,2,24]]},"abstract":"<jats:p>Cardiovascular disease is a major cause of morbidity and mortality in patients with impaired renal function. Dyslipidemia has been established as a well-known traditional risk factor for cardiovascular disease (CVD) in the general population and it is well known that patients with chronic kidney disease (CKD) exhibit significant alterations in lipoprotein metabolism. In this review, the pathogenesis and treatment of CKD-induced dyslipidemia are discussed. Studies on lipid abnormalities in predialysis, hemodialysis and peritoneal dialysis patients are analyzed. In addition, the results of the studies that tested the effects of the hypolipidemic drugs on cardiovascular morbidity and mortality in patients with CKD are reported.<\/jats:p>","DOI":"10.2174\/1874192401105010041","type":"journal-article","created":{"date-parts":[[2011,3,28]],"date-time":"2011-03-28T07:39:12Z","timestamp":1301297952000},"page":"41-48","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Dyslipidemia Associated with Chronic Kidney Disease"],"prefix":"10.2174","volume":"5","author":[{"given":"Vasilis","family":"Tsimihodimos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoi","family":"Mitrogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Elisaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.ajkd.2007.12.016","volume":"51","author":"Whaley-Connell AT","year":"2008","unstructured":"Whaley-Connell AT, Sowers JR, Stevens LA, et al. \n                CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004 \n                Am J Kidney Dis  \n                2008; \n                51\n                : S13-20.","journal-title":"Am J Kidney Dis"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MNH.0b013e328327b360","volume":"18","author":"Yamamoto S","year":"2009","unstructured":"Yamamoto S, Kon V. \n                Mechanisms for increased cardiovascular disease in chronic kidney dysfunction \n                Curr Opin Nephrol Hypertens  \n                2009; \n                18\n                : 181-8.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/eurheartj\/ehl455","volume":"28","author":"Van Biesen W","year":"2007","unstructured":"Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. \n                The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years \n                Eur Heart J  \n                2007; \n                28\n                : 478-83.","journal-title":"Eur Heart J"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(00)02456-9","volume":"356","author":"Baigent C","year":"2000","unstructured":"Baigent C, Burbury K, Wheeler D. \n                Premature cardiovascular disease in chronic renal failure \n                Lancet  \n                2000; \n                356\n                : 147-52.","journal-title":"Lancet"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","volume":"108","author":"Sarnak MJ","year":"2003","unstructured":"Sarnak MJ, Levey AS, Schoolwerth AC, et al. \n                Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research Clinical Cardiology, and Epidemiology and Prevention \n                Circulation  \n                2003; \n                108\n                : 2154-69.","journal-title":"Circulation"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1681\/ASN.2005121273","volume":"17","author":"Hallan SI","year":"2006","unstructured":"Hallan SI, Coresh J, Astor BC, et al. \n                International comparison of the relationship of chronic kidney disease prevalence and ESRD risk \n                J Am Soc Nephrol  \n                2006; \n                17\n                : 2275-84.","journal-title":"J Am Soc Nephrol"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"Go AS","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. \n                Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization \n                N Engl J Med  \n                2004; \n                351\n                : 1296-305.","journal-title":"N Engl J Med"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2796.2006.01679.x","volume":"260","author":"Klausen KP","year":"2006","unstructured":"Klausen KP, Scharling H, Jensen JS. \n                Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases \n                J Intern Med  \n                2006; \n                260\n                : 231-7.","journal-title":"J Intern Med"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ki.1996.201","volume":"49","author":"Parfrey PS","year":"1996","unstructured":"Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. \n                Outcome and risk factors of ischemic heart disease in chronic uremia \n                Kidney Int  \n                1996; \n                49\n                : 1428-34.","journal-title":"Kidney Int"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","volume":"32","author":"Foley RN","year":"1998","unstructured":"Foley RN, Parfrey PS, Sarnak MJ. \n                Clinical epidemiology of cardiovascular disease in chronic renal disease \n                Am J Kidney Dis  \n                1998; \n                32\n                : S112-9.","journal-title":"Am J Kidney Dis"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrcardio.2009.121","volume":"6","author":"van der Zee S","year":"2009","unstructured":"van der Zee S, Baber U, Elmariah S, Winston J, Fuster V. \n                Cardiovascular risk factors in patients with chronic kidney disease \n                Nat Rev Cardiol  \n                2009; \n                6\n                : 580-9.","journal-title":"Nat Rev Cardiol"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1001\/archinte.161.22.2657","volume":"161","author":"Magnus P","year":"2001","unstructured":"Magnus P, Beaglehole R. \n                The real contribution of the major risk factors to the coronary epidemics: time to end the \u201conly-50%\u201d myth \n                Arch Intern Med  \n                2001; \n                161\n                : 2657-60.","journal-title":"Arch Intern Med"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1046\/j.1523-1755.2002.00600.x","volume":"62","author":"Himmelfarb J","year":"2002","unstructured":"Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. \n                The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia \n                Kidney Int  \n                2002; \n                62\n                : 1524-38.","journal-title":"Kidney Int"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1056\/NEJMoa055373","volume":"355","author":"Wang TJ","year":"2006","unstructured":"Wang TJ, Gona P, Larson MG, et al. \n                Multiple biomarkers for the prediction of first major cardiovascular events and death \n                N Engl J Med  \n                2006; \n                355\n                : 2631-9.","journal-title":"N Engl J Med"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/ndt\/gfm418","volume":"22","author":"Addabbo F","year":"2007","unstructured":"Addabbo F, Mallamaci F, Leonardis D, et al. \n                Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function \n                Nephrol Dial Transplant  \n                2007; \n                22\n                : 3521-6.","journal-title":"Nephrol Dial Transplant"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.ajkd.2005.09.014","volume":"47","author":"Honda H","year":"2006","unstructured":"Honda H, Qureshi AR, Heimburger O, et al. \n                Serum albumin C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD \n                Am J Kidney Dis  \n                2006; \n                47\n                : 139-48.","journal-title":"Am J Kidney Dis"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","volume":"370","author":"Lewington S","year":"2007","unstructured":"Lewington S, Whitlock G, Clarke R, et al. \n                Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths \n                Lancet  \n                2007; \n                370\n                : 1829-39.","journal-title":"Lancet"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1159\/000144024","volume":"28","author":"Tsimihodimos V","year":"2008","unstructured":"Tsimihodimos V, Dounousi E, Siamopoulos KC. \n                Dyslipidemia in chronic kidney disease an approach to pathogenesis and treatment \n                Am J Nephrol  \n                2008; \n                28\n                : 958-73.","journal-title":"Am J Nephrol"},{"key":"refR19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.jrn.2008.10.011","volume":"19","author":"Kaysen GA","year":"2009","unstructured":"Kaysen GA. \n                Lipid and lipoprotein metabolism in chronic kidney disease \n                J Ren Nutr  \n                2009; \n                19\n                : 73-.","journal-title":"J Ren Nutr"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MOL.0b013e32832dd832","volume":"20","author":"Attman PO","year":"2009","unstructured":"Attman PO, Samuelsson O. \n                Dyslipidemia of kidney disease \n                Curr Opin Lipidol  \n                2009; \n                20\n                : 293-9.","journal-title":"Curr Opin Lipidol"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1542-4758.2006.01168.x","volume":"10","author":"Vaziri ND","year":"2006","unstructured":"Vaziri ND, Moradi H. \n                Mechanisms of dyslipidemia of chronic renal failure \n                Hemodial Int  \n                2006; \n                10\n                : 1-7.","journal-title":"Hemodial Int"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1681\/ASN.2006091006","volume":"18","author":"Kwan BC","year":"2007","unstructured":"Kwan BC, Kronenberg F, Beddhu S, Cheung AK. \n                Lipoprotein metabolism and lipid management in chronic kidney disease \n                J Am Soc Nephrol  \n                2007; \n                18\n                : 1246-61.","journal-title":"J Am Soc Nephrol"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1523-1755.1998.00898.x","volume":"53","author":"Fliser D","year":"1998","unstructured":"Fliser D, Pacini G, Engelleiter R, et al. \n                Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease \n                Kidney Int  \n                1998; \n                53\n                : 1343-7.","journal-title":"Kidney Int"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2337\/diabetes.51.4.1226","volume":"51","author":"Sechi LA","year":"2002","unstructured":"Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S. \n                Abnormalities of glucose metabolism in patients with early renal failure \n                Diabetes  \n                2002; \n                51\n                : 1226-32.","journal-title":"Diabetes"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.metabol.2005.01.028","volume":"54","author":"Charlesworth JA","year":"2005","unstructured":"Charlesworth JA, Kriketos AD, Jones JE, Erlich JH, Campbell LV, Peake PW. \n                Insulin resistance and postprandial triglyceride levels in primary renal disease \n                Metabolism  \n                2005; \n                54\n                : 821-.","journal-title":"Metabolism"},{"key":"refR26","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1046\/j.1523-1755.63.s84.34.x","volume":"84","author":"Prinsen BH","year":"2003","unstructured":"Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. \n                Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms \n                Kidney Int Suppl  \n                2003; \n                84\n                : S121-4.","journal-title":"Kidney Int Suppl"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/ki.1996.515","volume":"50","author":"Vaziri ND","year":"1996","unstructured":"Vaziri ND, Liang K. \n                Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure \n                Kidney Int  \n                1996; \n                50\n                : 1928-35.","journal-title":"Kidney Int"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/ki.1996.192","volume":"49","author":"Cheung AK","year":"1996","unstructured":"Cheung AK, Parker CJ, Ren K, Iverius PH. \n                Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma \n                Kidney Int  \n                1996; \n                49\n                : 1360-71.","journal-title":"Kidney Int"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1194\/jlr.P900003-JLR200","volume":"50","author":"Chan DT","year":"2009","unstructured":"Chan DT, Dogra GK, Irish AB, et al. \n                Chronic kidney disease delays VLDL apoB-100 particle catabolism: potential role of apo C-III \n                J Lipid Res  \n                2009; \n                50\n                : 2524-31.","journal-title":"J Lipid Res"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000057457","volume":"25","author":"Moberly JB","year":"1999","unstructured":"Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. \n                Apolipoprotein C-III hypertriglyceridemia and triglyceride-rich lipoproteins in uremia \n                Miner Electrolyte Metab  \n                1999; \n                25\n                : 258-62.","journal-title":"Miner Electrolyte Metab"},{"key":"refR31","first-page":"38","volume":"87","author":"Bagdade J","year":"1976","unstructured":"Bagdade J, Casaretto A, Albers J. \n                Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man \n                J Lab Clin Med  \n                1976; \n                87\n                : 38-48.","journal-title":"J Lab Clin Med"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1046\/j.1523-1755.2003.00019.x","volume":"63","author":"Hirano T","year":"2003","unstructured":"Hirano T, Sakaue T, Misaki A, et al. \n                Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII \n                Kidney Int  \n                2003; \n                63\n                : 2171-77.","journal-title":"Kidney Int"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/ki.1990.58","volume":"37","author":"Akmal M","year":"1990","unstructured":"Akmal M, Kasim SE, Soliman AR, Massry SG. \n                Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure \n                Kidney Int  \n                1990; \n                37\n                : 854-.","journal-title":"Kidney Int"},{"key":"refR34","first-page":"F925","volume":"273","author":"Vaziri ND","year":"1997","unstructured":"Vaziri ND, Wang XQ, Liang K. \n                Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure \n                Am J Physiol  \n                1997; \n                273\n                : F925-30.","journal-title":"Am J Physiol"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.1995.73","volume":"47","author":"Vega GL","year":"1995","unstructured":"Vega GL, Toto RD, Grundy SM. \n                Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia \n                Kidney Int  \n                1995; \n                47\n                : 579-86.","journal-title":"Kidney Int"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/oxfordjournals.ndt.a092490","volume":"8","author":"Warwick GL","year":"1993","unstructured":"Warwick GL, Packard CJ. \n                Lipoprotein metabolism in the nephrotic syndrome \n                Nephrol Dial Transplant  \n                1993; \n                8\n                : 385-96.","journal-title":"Nephrol Dial Transplant"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-2143(97)90038-X","volume":"130","author":"Liang K","year":"1997","unstructured":"Liang K, Vaziri ND. \n                Gene expression of lipoprotein lipase in experimental nephrosis \n                J Lab Clin Med  \n                1997; \n                130\n                : 387-94.","journal-title":"J Lab Clin Med"},{"key":"refR38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1523-1755.2001.00478.x","volume":"59","author":"Shearer GC","year":"2001","unstructured":"Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA. \n                Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome \n                Kidney Int  \n                2001; \n                59\n                : 179-89.","journal-title":"Kidney Int"},{"key":"refR39","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1046\/j.1523-1755.63.s84.3.x","volume":"63","author":"Attman PO","year":"2003","unstructured":"Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P. \n                Dialysis modalities and dyslipidemia \n                Kidney Int Suppl  \n                2003; \n                63\n                : S110-2.","journal-title":"Kidney Int Suppl"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJM197712222972502","volume":"297","author":"Mordasini R","year":"1977","unstructured":"Mordasini R, Frey F, Flury W, Klose G, Greten H. \n                Selective deficiency of hepatic triglyceride lipase in uremic patients \n                N Engl J Med  \n                1977; \n                297\n                : 1362-66.","journal-title":"N Engl J Med"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/ki.1992.238","volume":"41","author":"Shoji T","year":"1992","unstructured":"Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. \n                Impaired metabolism of high density lipoprotein in uremic patients \n                Kidney Int  \n                1992; \n                41\n                : 1653-61.","journal-title":"Kidney Int"},{"key":"refR42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.0954-6820.1978.tb08426.x","volume":"204","author":"Huttunen JK","year":"1978","unstructured":"Huttunen JK, Pasternack A, Vanttinen T, Ehnholm C, Nikkila EA. \n                Lipoprotein metabolism in patients with chronic uremia. Effect of hemodialysis on serum lipoproteins and postheparin plasma triglyceride lipases \n                Acta Med Scand  \n                1978; \n                204\n                : 211-8.","journal-title":"Acta Med Scand"},{"key":"refR43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000080591","volume":"24","author":"Katopodis KP","year":"2004","unstructured":"Katopodis KP, Elisaf M, Balafa O, et al. \n                Influence of the type of membrane and heparin on serum lipid parameters during a dialysis session: a pilot study \n                Am J Nephrol  \n                2004; \n                24\n                : 469-73.","journal-title":"Am J Nephrol"},{"key":"refR44","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/ki.1988.81","volume":"33","author":"Schrader J","year":"1988","unstructured":"Schrader J, Stibbe W, Armstrong VW, et al. \n                Comparison of low molecular weight heparin to standard heparin in hemodialysis\/hemofiltration \n                Kidney Int  \n                1988; \n                33\n                : 890-6.","journal-title":"Kidney Int"},{"key":"refR45","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/ndt\/gfh415","volume":"19","author":"Wanner C","year":"2004","unstructured":"Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. \n                Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients \n                Nephrol Dial Transplant  \n                2004; \n                19\n                : 2570-5.","journal-title":"Nephrol Dial Transplant"},{"key":"refR46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00002480-200105000-00014","volume":"47","author":"Ottosson P","year":"2001","unstructured":"Ottosson P, Attman PO, Knight C, Samuelsson O, Weiss L, Alaupovic P. \n                Do high-flux dialysis membranes affect renal dyslipidemia? \n                ASAIO J  \n                2001; \n                47\n                : 229-34.","journal-title":"ASAIO J"},{"key":"refR47","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1046\/j.1523-1755.63.s84.23.x","volume":"84","author":"Kronenberg F","year":"2003","unstructured":"Kronenberg F, Lingenhel A, Neyer U, et al. \n                Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients \n                Kidney Int Suppl  \n                2003; \n                84\n                : S113-6.","journal-title":"Kidney Int Suppl"},{"key":"refR48","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/089686080002000307","volume":"20","author":"Johansson AC","year":"2000","unstructured":"Johansson AC, Samuelsson O, Attman PO, et al. \n                Dyslipidemia in peritoneal dialysis--relation to dialytic variables \n                Perit Dial Int  \n                2000; \n                20\n                : 306-14.","journal-title":"Perit Dial Int"},{"key":"refR49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/089686080102100308","volume":"21","author":"Bredie SJ","year":"2001","unstructured":"Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. \n                Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism \n                Perit Dial Int  \n                2001; \n                21\n                : 275-81.","journal-title":"Perit Dial Int"},{"key":"refR50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000105123","volume":"27","author":"Babazono T","year":"2007","unstructured":"Babazono T, Nakamoto H, Kasai K, et al. \n                Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis \n                Am J Nephrol  \n                2007; \n                27\n                : 409-15.","journal-title":"Am J Nephrol"},{"key":"refR51","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/ndt\/12.7.1381","volume":"12","author":"Liang K","year":"1997","unstructured":"Liang K, Vaziri ND. \n                Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure \n                Nephrol Dial Transplant  \n                1997; \n                12\n                : 1381-6.","journal-title":"Nephrol Dial Transplant"},{"key":"refR52","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1046\/j.1523-1755.2003.00941.x","volume":"63","author":"Vaziri ND","year":"2003","unstructured":"Vaziri ND. \n                Molecular mechanisms of lipid disorders in nephrotic syndrome \n                Kidney Int  \n                2003; \n                63\n                : 1964-76.","journal-title":"Kidney Int"},{"key":"refR53","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1046\/j.1523-1755.2003.00911.x","volume":"63","author":"Vaziri ND","year":"2003","unstructured":"Vaziri ND, Sato T, Liang K. \n                Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis \n                Kidney Int  \n                2003; \n                63\n                : 1756-63.","journal-title":"Kidney Int"},{"key":"refR54","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/ki.1996.388","volume":"50","author":"Vaziri ND","year":"1996","unstructured":"Vaziri ND, Liang KH. \n                Down-regulation of hepatic LDL receptor expression in experimental nephrosis \n                Kidney Int  \n                1996; \n                50\n                : 887-93.","journal-title":"Kidney Int"},{"key":"refR55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0021-9150(00)00710-3","volume":"157","author":"Deighan CJ","year":"2001","unstructured":"Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. \n                The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria \n                Atherosclerosis  \n                2001; \n                157\n                : 211-0.","journal-title":"Atherosclerosis"},{"key":"refR56","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1046\/j.1523-1755.2002.00319.x","volume":"61","author":"Vaziri ND","year":"2002","unstructured":"Vaziri ND, Liang K. \n                Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome \n                Kidney Int  \n                2002; \n                61\n                : 1769-75.","journal-title":"Kidney Int"},{"key":"refR57","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/ki.1995.500","volume":"48","author":"Vaziri ND","year":"1995","unstructured":"Vaziri ND, Liang KH. \n                Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis \n                Kidney Int  \n                1995; \n                48\n                : 1979-85.","journal-title":"Kidney Int"},{"key":"refR58","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/ndt\/13.6.1446","volume":"13","author":"Pahl MV","year":"1998","unstructured":"Pahl MV, Oveisi F, Khamiseh G, Vaziri ND. \n                Intestinal absorption and biliary secretion of cholesterol in rats with nephrotic syndrome \n                Nephrol Dial Transplant  \n                1998; \n                13\n                : 1446-51.","journal-title":"Nephrol Dial Transplant"},{"key":"refR59","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/ndt\/13.9.2281","volume":"13","author":"Rajman I","year":"1998","unstructured":"Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. \n                Low-density lipoprotein subfraction profiles in chronic renal failure \n                Nephrol Dial Transplant  \n                1998; \n                13\n                : 2281-7.","journal-title":"Nephrol Dial Transplant"},{"key":"refR60","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S0272-6386(00)70255-1","volume":"35","author":"Deighan CJ","year":"2000","unstructured":"Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. \n                Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation \n                Am J Kidney Dis  \n                2000; \n                35\n                : 852-62.","journal-title":"Am J Kidney Dis"},{"key":"refR61","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.mcna.2004.11.002","volume":"89","author":"Farbakhsh K","year":"2005","unstructured":"Farbakhsh K, Kasiske BL. \n                Dyslipidemias in patients who have chronic kidney disease \n                Med Clin North Am  \n                2005; \n                89\n                : 689-99.","journal-title":"Med Clin North Am"},{"key":"refR62","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1046\/j.1523-1755.1999.00375.x","volume":"55","author":"Attman PO","year":"1999","unstructured":"Attman PO, Samuelsson OG, Moberly J, et al. \n                Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis \n                Kidney Int  \n                1999; \n                55\n                : 1536-42.","journal-title":"Kidney Int"},{"key":"refR63","first-page":"S41","volume":"56","author":"Wheeler DC","year":"1996","unstructured":"Wheeler DC. \n                Abnormalities of lipoprotein metabolism in CAPD patients \n                Kidney Int Suppl  \n                1996; \n                56\n                : S41-6.","journal-title":"Kidney Int Suppl"},{"key":"refR64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000187140","volume":"63","author":"Kagan A","year":"1993","unstructured":"Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. \n                Heterogeneity in peritoneal transport during continuous ambulatory peritoneal dialysis and its impact on ultrafiltration, loss of macromolecules and plasma level of proteins, lipids and lipoproteins \n                Nephron  \n                1993; \n                63\n                : 32-42.","journal-title":"Nephron"},{"key":"refR65","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/089686089701700302","volume":"17","author":"Siamopoulos KC","year":"1997","unstructured":"Siamopoulos KC, Elisaf M. \n                Is CAPD atherogenic? \n                Perit Dial Int  \n                1997; \n                17\n                : 227-31.","journal-title":"Perit Dial Int"},{"key":"refR66","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/ki.1990.74","volume":"37","author":"Kagan A","year":"1990","unstructured":"Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. \n                Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels \n                Kidney Int  \n                1990; \n                37\n                : 980-0.","journal-title":"Kidney Int"},{"key":"refR67","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/ndt\/7.10.1026","volume":"7","author":"Kandoussi A","year":"1992","unstructured":"Kandoussi A, Cachera C, Reade R, Pagniez D, Fruchart JC, Tacquet A. \n                Apo AIV in plasma and dialysate fluid of CAPD patients: comparison with other apolipoproteins \n                Nephrol Dial Transplant  \n                1992; \n                7\n                : 1026-9.","journal-title":"Nephrol Dial Transplant"},{"key":"refR68","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"Chertow GM","year":"2002","unstructured":"Chertow GM, Burke SK, Raggi P. \n                Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients \n                Kidney Int  \n                2002; \n                62\n                : 245-52.","journal-title":"Kidney Int"},{"key":"refR69","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0272-6386(99)70147-2","volume":"33","author":"Milionis HJ","year":"1999","unstructured":"Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC. \n                Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure \n                Am J Kidney Dis  \n                1999; \n                33\n                : 1100-6.","journal-title":"Am J Kidney Dis"},{"key":"refR70","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","volume":"80","author":"Utermann G","year":"1987","unstructured":"Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. \n                Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma \n                J Clin Invest  \n                1987; \n                80\n                : 458-65.","journal-title":"J Clin Invest"},{"key":"refR71","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","volume":"38","author":"Kronenberg F","year":"1997","unstructured":"Kronenberg F, Trenkwalder E, Lingenhel A, et al. \n                Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation \n                J Lipid Res  \n                1997; \n                38\n                : 1755-63.","journal-title":"J Lipid Res"},{"key":"refR72","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/01.ATV.16.8.905","volume":"16","author":"Kostner KM","year":"1996","unstructured":"Kostner KM, Maurer G, Huber K, et al. \n                Urinary excretion of apo(a) fragments. Role in apo(a) catabolism \n                Arterioscler Thromb Vasc Biol  \n                1996; \n                16\n                : 905-11.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"refR73","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1681\/ASN.V351156","volume":"3","author":"Haffner SM","year":"1992","unstructured":"Haffner SM, Gruber KK, Aldrete G Jr, Morales PA, Stern MP, Tuttle KR. \n                Increased lipoprotein(a) concentrations in chronic renal failure \n                J Am Soc Nephrol  \n                1992; \n                3\n                : 1156-62.","journal-title":"J Am Soc Nephrol"},{"key":"refR74","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000045073","volume":"79","author":"Bairaktari","year":"1998","unstructured":"Bairaktari  \n                        , Elisaf M, Tsolas O, Siamopoulos KC. \n                Serum Lp(a) levels in patients with moderate renal failure \n                Nephron  \n                1998; \n                79\n                : 367-8.","journal-title":"Nephron"},{"key":"refR75","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/ki.1997.503","volume":"52","author":"Trenkwalder E","year":"1997","unstructured":"Trenkwalder E, Gruber A, Konig P, Dieplinger H, Kronenberg F. \n                Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease \n                Kidney Int  \n                1997; \n                52\n                : 1685-92.","journal-title":"Kidney Int"},{"key":"refR76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","volume":"11","author":"Kronenberg F","year":"2000","unstructured":"Kronenberg F, Kuen E, Ritz E, et al. \n                Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure \n                J Am Soc Nephrol  \n                2000; \n                11\n                : 105-5.","journal-title":"J Am Soc Nephrol"},{"key":"refR77","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","volume":"10","author":"Kronenberg F","year":"1999","unstructured":"Kronenberg F, Neyer U, Lhotta K, et al. \n                The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up \n                J Am Soc Nephrol  \n                1999; \n                10\n                : 1027-36.","journal-title":"J Am Soc Nephrol"},{"key":"refR78","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1161\/01.CIR.0000038946.91899.BB","volume":"106","author":"Longenecker JC","year":"2002","unstructured":"Longenecker JC, Klag MJ, Marcovina SM, et al. \n                Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study \n                Circulation  \n                2002; \n                106\n                : 2812-8.","journal-title":"Circulation"},{"key":"refR79","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","volume":"6","author":"Kronenberg F","year":"1995","unstructured":"Kronenberg F, Konig P, Neyer U, et al. \n                Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis \n                J Am Soc Nephrol  \n                1995; \n                6\n                : 110-20.","journal-title":"J Am Soc Nephrol"},{"key":"refR80","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1046\/j.1523-1755.1998.00880.x","volume":"53","author":"Stenvinkel P","year":"1998","unstructured":"Stenvinkel P, Heimburger O, Tuck CH, Berglund L. \n                Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure \n                Kidney Int  \n                1998; \n                53\n                : 1336-42.","journal-title":"Kidney Int"},{"key":"refR81","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","volume":"55","author":"Stenvinkel P","year":"1999","unstructured":"Stenvinkel P, Heimburger O, Paultre F, et al. \n                Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure \n                Kidney Int  \n                1999; \n                55\n                : 1899-911.","journal-title":"Kidney Int"},{"key":"refR82","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","volume":"55","author":"Zimmermann J","year":"1999","unstructured":"Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. \n                Inflammation enhances cardiovascular risk and mortality in hemodialysis patients \n                Kidney Int  \n                1999; \n                55\n                : 648-58.","journal-title":"Kidney Int"},{"key":"refR83","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","volume":"71","author":"Frischmann ME","year":"2007","unstructured":"Frischmann ME, Kronenberg F, Trenkwalder E, et al. \n                In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients \n                Kidney Int  \n                2007; \n                71\n                : 1036-43.","journal-title":"Kidney Int"},{"key":"refR84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000188831","volume":"72","author":"Heimburger O","year":"1996","unstructured":"Heimburger O, Stenvinkel P, Berglund L, Tranoeus A, Lindholm B. \n                Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose \n                Nephron  \n                1996; \n                72\n                : 135-44.","journal-title":"Nephron"},{"key":"refR85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.ndt.a090858","volume":"10","author":"Wanner C","year":"1995","unstructured":"Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P. \n                Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients \n                Nephrol Dial Transplant  \n                1995; \n                10\n                : 75-81.","journal-title":"Nephrol Dial Transplant"},{"key":"refR86","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","volume":"119","author":"Wanner C","year":"1993","unstructured":"Wanner C, Rader D, Bartens W, et al. \n                Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome \n                Ann Intern Med  \n                1993; \n                119\n                : 263-9.","journal-title":"Ann Intern Med"},{"key":"refR87","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.V981474","volume":"9","author":"de Sain-van der Velden MG","year":"1998","unstructured":"de Sain-van der Velden MG, Reijngoud DJ, Kaysen GA, et al. \n                Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome \n                J Am Soc Nephrol  \n                1998; \n                9\n                : 1474-81.","journal-title":"J Am Soc Nephrol"},{"key":"refR88","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ncpcardio0500","volume":"3","author":"Kontush A","year":"2006","unstructured":"Kontush A, Chapman MJ. \n                Antiatherogenic small, dense HDL--guardian angel of the arterial wall? \n                Nat Clin Pract Cardiovasc Med  \n                2006; \n                3\n                : 144-53.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"refR89","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0021-9150(00)00603-1","volume":"153","author":"Despres JP","year":"2000","unstructured":"Despres JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. \n                HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study \n                Atherosclerosis  \n                2000; \n                153\n                : 263-72.","journal-title":"Atherosclerosis"},{"key":"refR90","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0272-6386(12)80030-8","volume":"21","author":"Attman PO","year":"1993","unstructured":"Attman PO, Samuelsson O, Alaupovic P. \n                Lipoprotein metabolism and renal failure \n                Am J Kidney Dis  \n                1993; \n                21\n                : 573-92.","journal-title":"Am J Kidney Dis"},{"key":"refR91","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/ndt\/14.6.1462","volume":"14","author":"Vaziri ND","year":"1999","unstructured":"Vaziri ND, Deng G, Liang K. \n                Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure \n                Nephrol Dial Transplant  \n                1999; \n                14\n                : 1462-6.","journal-title":"Nephrol Dial Transplant"},{"key":"refR92","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00734.x","volume":"59","author":"Vaziri ND","year":"2001","unstructured":"Vaziri ND, Liang K, Parks JS. \n                Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure \n                Kidney Int  \n                2001; \n                59\n                : 2192-6.","journal-title":"Kidney Int"},{"key":"refR93","first-page":"S26","volume":"00","author":"Guarnieri GF","year":"1978","unstructured":"Guarnieri GF, Moracchiello M, Campanacci L, et al. \n                Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia \n                Kidney Int Suppl  \n                1978; \n                00\n                : S26-30.","journal-title":"Kidney Int Suppl"},{"key":"refR94","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1046\/j.1523-1755.2003.00285.x","volume":"64","author":"Kimura H","year":"2003","unstructured":"Kimura H, Miyazaki R, Imura T, et al. \n                Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels \n                Kidney Int  \n                2003; \n                64\n                : 1829-37.","journal-title":"Kidney Int"},{"key":"refR95","first-page":"813","volume":"17","author":"Dirican M","year":"2004","unstructured":"Dirican M, Akca R, Sarandol E, Dilek K. \n                Serum paraoxonase activity in uremic predialysis and hemodialysis patients \n                J Nephrol  \n                2004; \n                17\n                : 813-.","journal-title":"J Nephrol"},{"key":"refR96","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/089686080402400618","volume":"24","author":"Liberopoulos EN","year":"2004","unstructured":"Liberopoulos EN, Papavasiliou E, Miltiadous GA, et al. \n                Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis \n                Perit Dial Int  \n                2004; \n                24\n                : 580-9.","journal-title":"Perit Dial Int"},{"key":"refR97","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1681\/ASN.V591703","volume":"5","author":"Blankestijn PJ","year":"1995","unstructured":"Blankestijn PJ, Vos PF, Rabelink TJ, van Rijn HJ, Jansen H, Koomans HA. \n                High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients \n                J Am Soc Nephrol  \n                1995; \n                5\n                : 1703-8.","journal-title":"J Am Soc Nephrol"},{"key":"refR98","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000188479","volume":"69","author":"Docci D","year":"1995","unstructured":"Docci D, Capponcini C, Mengozzi S, Baldrati L, Neri L, Feletti C. \n                Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients \n                Nephron  \n                1995; \n                69\n                : 323-6.","journal-title":"Nephron"},{"key":"refR99","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/0272-6386(95)90127-2","volume":"25","author":"Jung K","year":"1995","unstructured":"Jung K, Scheifler A, Schulze BD, Scholz M. \n                Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate \n                Am J Kidney Dis  \n                1995; \n                25\n                : 584-8.","journal-title":"Am J Kidney Dis"},{"key":"refR100","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.V8121889","volume":"8","author":"Koch M","year":"1997","unstructured":"Koch M, Kutkuhn B, Trenkwalder E, et al. \n                Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients \n                J Am Soc Nephrol  \n                1997; \n                8\n                : 1889-98.","journal-title":"J Am Soc Nephrol"},{"key":"refR101","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000182627","volume":"31","author":"Degoulet P","year":"1982","unstructured":"Degoulet P, Legrain M, Reach I, et al. \n                Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study \n                Nephron  \n                1982; \n                31\n                : 103-.","journal-title":"Nephron"},{"key":"refR102","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","volume":"293","author":"Shlipak MG","year":"2005","unstructured":"Shlipak MG, Fried LF, Cushman M, et al. \n                Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors \n                JAMA  \n                2005; \n                293\n                : 1737-45.","journal-title":"JAMA"},{"key":"refR103","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","volume":"63","author":"Kalantar-Zadeh K","year":"2003","unstructured":"Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. \n                Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients \n                Kidney Int  \n                2003; \n                63\n                : 793-808.","journal-title":"Kidney Int"},{"key":"refR104","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","volume":"15","author":"Lowrie EG","year":"1990","unstructured":"Lowrie EG, Lew NL. \n                Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities \n                Am J Kidney Dis  \n                1990; \n                15\n                : 458-82.","journal-title":"Am J Kidney Dis"},{"key":"refR105","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1046\/j.1523-1755.2002.00324.x","volume":"61","author":"Iseki K","year":"2002","unstructured":"Iseki K, Yamazato M, Tozawa M, Takishita S. \n                Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients \n                Kidney Int  \n                2002; \n                61\n                : 1887-93.","journal-title":"Kidney Int"},{"key":"refR106","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","volume":"291","author":"Liu Y","year":"2004","unstructured":"Liu Y, Coresh J, Eustace JA, et al. \n                Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition \n                JAMA  \n                2004; \n                291\n                : 451-9.","journal-title":"JAMA"},{"key":"refR107","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2006070795","volume":"18","author":"Kilpatrick RD","year":"2007","unstructured":"Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. \n                Association between serum lipids and survival in hemodialysis patients and impact of race \n                J Am Soc Nephrol  \n                2007; \n                18\n                : 293-303.","journal-title":"J Am Soc Nephrol"},{"key":"refR108","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1016\/S0272-6386(03)00264-6","volume":"41","year":"2003","unstructured":"K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease \n                Am J Kidney Dis  \n                2003; \n                41\n                : I-91.","journal-title":"Am J Kidney Dis"},{"key":"refR109","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","unstructured":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) \n                JAMA  \n                2001; \n                285\n                : 2486-97.","journal-title":"JAMA"},{"key":"refR110","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/ajkd.2001.22070","volume":"37","author":"Tonelli M","year":"2001","unstructured":"Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. \n                Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency \n                Am J Kidney Dis  \n                2001; \n                37\n                : 484-9.","journal-title":"Am J Kidney Dis"},{"key":"refR111","first-page":"263","volume":"15","author":"Harris K","year":"2002","unstructured":"Harris K, Thomas M, Short C, Moore R. \n                Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients \n                J Nephrol  \n                2002; \n                15\n                : 263-9.","journal-title":"J Nephrol"},{"key":"refR112","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"Baigent C","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, et al. \n                Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins \n                Lancet  \n                2005; \n                366\n                : 1267-78.","journal-title":"Lancet"},{"key":"refR113","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.amjcard.2004.10.008","volume":"95","author":"Lemos PA","year":"2005","unstructured":"Lemos PA, Serruys PW, de Feyter P, et al. \n                Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy) \n                Am J Cardiol  \n                2005; \n                95\n                : 445-51.","journal-title":"Am J Cardiol"},{"key":"refR114","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","volume":"138","author":"Tonelli M","year":"2003","unstructured":"Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. \n                Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency \n                Ann Intern Med  \n                2003; \n                138\n                : 98-104.","journal-title":"Ann Intern Med"},{"key":"refR115","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","volume":"110","author":"Tonelli M","year":"2004","unstructured":"Tonelli M, Isles C, Curhan GC, et al. \n                Effect of pravastatin on cardiovascular events in people with chronic kidney disease \n                Circulation  \n                2004; \n                110\n                : 1557-63.","journal-title":"Circulation"},{"key":"refR116","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2006.06.003","volume":"117","author":"Holdaas H","year":"2007","unstructured":"Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. \n                The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials \n                Int J Cardiol  \n                2007; \n                117\n                : 64-74.","journal-title":"Int J Cardiol"},{"key":"refR117","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","volume":"51","author":"Shepherd J","year":"2008","unstructured":"Shepherd J, Kastelein JJ, Bittner V, et al. \n                Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study \n                J Am Coll Cardiol  \n                2008; \n                51\n                : 1448-54.","journal-title":"J Am Coll Cardiol"},{"key":"refR118","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.ajkd.2008.11.025","volume":"53","author":"Koren MJ","year":"2009","unstructured":"Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP. \n                Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD \n                Am J Kidney Dis  \n                2009; \n                53\n                : 741-50.","journal-title":"Am J Kidney Dis"},{"key":"refR119","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","year":"2002","unstructured":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial \n                Lancet  \n                2002; \n                360\n                : 7-22.","journal-title":"Lancet"},{"key":"refR120","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever PS","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, et al. \n                Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial \n                Lancet  \n                2003; \n                361\n                : 1149-58.","journal-title":"Lancet"},{"key":"refR121","first-page":"CD007784","volume":"2","author":"Navaneethan SD","year":"2009","unstructured":"Navaneethan SD, Pansini F, Perkovic V, et al. \n                HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis \n                Cochrane Database Syst Rev  \n                2009; \n                2\n                : CD007784.","journal-title":"Cochrane Database Syst Rev"},{"key":"refR122","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1523-1755.2002.00109.x","volume":"61","author":"Seliger SL","year":"2002","unstructured":"Seliger SL, Weiss NS, Gillen DL, et al. \n                HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients \n                Kidney Int  \n                2002; \n                61\n                : 297-304.","journal-title":"Kidney Int"},{"key":"refR123","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.ajkd.2004.09.025","volume":"45","author":"Mason NA","year":"2005","unstructured":"Mason NA, Bailie GR, Satayathum S, et al. \n                HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients \n                Am J Kidney Dis  \n                2005; \n                45\n                : 119-26.","journal-title":"Am J Kidney Dis"},{"key":"refR124","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.ajkd.2007.07.023","volume":"50","author":"Goldfarb-Rumyantzev AS","year":"2007","unstructured":"Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK. \n                The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis \n                Am J Kidney Dis  \n                2007; \n                50\n                : 791-802.","journal-title":"Am J Kidney Dis"},{"key":"refR125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000080241","volume":"27","author":"Wanner C","year":"2004","unstructured":"Wanner C, Krane V, Marz W, et al. \n                Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics \n                Kidney Blood Press Res  \n                2004; \n                27\n                : 259-66.","journal-title":"Kidney Blood Press Res"},{"key":"refR126","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"Wanner C","year":"2005","unstructured":"Wanner C, Krane V, Marz W, et al. \n                Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis \n                N Engl J Med  \n                2005; \n                353\n                : 238-48.","journal-title":"N Engl J Med"},{"key":"refR127","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"Fellstrom BC","year":"2009","unstructured":"Fellstrom BC, Jardine AG, Schmieder RE, et al. \n                Rosuvastatin and cardiovascular events in patients undergoing hemodialysis \n                N Engl J Med  \n                2009; \n                360\n                : 1395-407.","journal-title":"N Engl J Med"},{"key":"refR128","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1744-9987.2006.00382.x","volume":"10","author":"Shoji T","year":"2006","unstructured":"Shoji T, Nishizawa Y. \n                Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines \n                Ther Apher Dial  \n                2006; \n                10\n                : 305-15.","journal-title":"Ther Apher Dial"},{"key":"refR129","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1681\/ASN.2006080919","volume":"17","author":"Ritz E","year":"2006","unstructured":"Ritz E, Wanner C. \n                Lipid changes and statins in chronic renal insufficiency \n                J Am Soc Nephrol  \n                2006; \n                17\n                : S226-30.","journal-title":"J Am Soc Nephrol"},{"key":"refR130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1592\/phco.27.3.412","volume":"27","author":"Backes JM","year":"2007","unstructured":"Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. \n                Fibrates: what have we learned in the past 40 years? \n                Pharmacotherapy  \n                2007; \n                27\n                : 412-24.","journal-title":"Pharmacotherapy"},{"key":"refR131","doi-asserted-by":"crossref","first-page":"19C","DOI":"10.1016\/j.amjcard.2006.11.017","volume":"99","author":"Brown WV","year":"2007","unstructured":"Brown WV. \n                Expert commentary: the safety of fibrates in lipid-lowering therapy \n                Am J Cardiol  \n                2007; \n                99\n                : 19C-21C.","journal-title":"Am J Cardiol"},{"key":"refR132","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","volume":"99","author":"Davidson MH","year":"2007","unstructured":"Davidson MH, Armani A, McKenney JM, Jacobson TA. \n                Safety considerations with fibrate therapy \n                Am J Cardiol  \n                2007; \n                99\n                : 3C-18C.","journal-title":"Am J Cardiol"},{"key":"refR133","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","volume":"66","author":"Tonelli M","year":"2004","unstructured":"Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. \n                Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency \n                Kidney Int  \n                2004; \n                66\n                : 1123-30.","journal-title":"Kidney Int"},{"key":"refR134","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinthera.2007.07.018","volume":"29","author":"Davidson MH","year":"2007","unstructured":"Davidson MH, Stein EA, Bays HE, et al. \n                Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g\/d to simvastatin 40 mg\/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study \n                Clin Ther  \n                2007; \n                29\n                : 1354-67.","journal-title":"Clin Ther"}],"container-title":["The Open Cardiovascular Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/\/contents\/volumes\/V5\/TOCMJ-5-41\/TOCMJ-5-41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/\/contents\/volumes\/V5\/TOCMJ-5-41\/TOCMJ-5-41.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/\/contents\/volumes\/V5\/TOCMJ-5-41\/TOCMJ-5-41.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:01:42Z","timestamp":1761289302000},"score":1,"resource":{"primary":{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/\/VOLUME\/5\/PAGE\/41\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,24]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2,24]]}},"alternative-id":["TOCMJ-5-41"],"URL":"https:\/\/doi.org\/10.2174\/1874192401105010041","relation":{},"ISSN":["1874-1924"],"issn-type":[{"value":"1874-1924","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2010-12-9","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-1-6","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-1-6","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-02-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}